Exit opportunities to Pharma/Biotech from consulting - Health Advances vs. IMS consulting group
Hi,
I am a life sciences researcher transitioning into healthcare consulting. I have a PhD in Biochemistry, currently a Postdoc in New York, and I have some consulting experience with startups. I currently have an offer from Health Advances and looking at interviews with IMS Consulting group in the next few weeks. I am eventually interested in transitioning to the business strategy side in a pharma/biotech. I was wondering what are the exit opportunities for pharma/biotech from these firms. Any inputs on work culture and brand recognition among these firms would also help my decision.
Thanks!
bump, also curious
IMS will skew towards more opportunities in payer and market access type roles, whereas HA will open up more opportunities in BD/NPP/Commercial planning. IMS has slight edge on prestige, but honestly that's irrelevant, as those hiring know who is good at what. IMS probably gets you further in the P&MA world, but at the expense of the more strategically focused roles that HA places you into. Oh, and don't forget, HA can niche you in the device and diagnostics world.
agree completely with this. only thing I would add is that I would say IMS skews broader than just payer/market access and into more sales/marketing roles as well. But the directionality is correct
Esse non repudiandae dolore placeat odit necessitatibus autem. Tenetur rerum sequi consequatur repellendus facilis architecto. Velit occaecati harum in voluptates rerum est.
Deserunt qui enim libero reprehenderit natus esse qui. Ut saepe ad dolore officia aut nulla ipsa. In in quo debitis dolore tempore. Quo atque a sint inventore qui nam voluptas.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...